Sarepta Therapeutics, Inc. SRPT
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD. We are also developing potential therapeutic candidates through our partnered program with Arrowhead for the treatment of Facioscapulohumeral muscular dystrophy ("FSHD"), myotonic dystrophy type 1 ("DM1"), Spinocerebellar ataxia ("SCA"), Idiopathic Pulmonary Fibrosis ("IPF"), Huntington's disease and other neuromuscular and skeletal diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.79B | $1.14B | $843.8M | $612.4M | $455.9M | $380.8M | $301.0M | $154.6M | $5.4M |
| Cost of revenue | $25.5M | — | — | — | — | — | — | — | — | $130.0K |
| Gross profit | $1.84B | — | — | — | — | — | — | — | — | $5.3M |
| R&D | — | — | — | — | — | — | — | $401.8M | $166.7M | $188.3M |
| SG&A | $491.7M | $557.9M | $481.9M | $451.4M | $282.7M | $317.9M | $284.8M | $207.8M | $122.7M | $83.7M |
| Total operating expenses | $2.90B | $1.68B | $1.51B | $1.47B | $1.16B | $1.10B | $1.09B | $644.7M | $326.2M | $272.2M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M | -$564.2M | -$705.6M | -$343.6M | -$171.6M | -$266.7M |
| Interest expense | $38.1M | $18.4M | $22.0M | $53.2M | $63.5M | $59.9M | $30.7M | $33.7M | $5.8M | $1.9M |
| Pre-tax income | -$702.2M | $260.8M | -$520.1M | -$690.0M | -$418.9M | -$553.1M | -$713.9M | -$362.6M | -$48.6M | -$267.3M |
| Income tax | $11.2M | $25.5M | $15.9M | $13.5M | $168.0K | $1.1M | $1.2M | $692.0K | $2.1M | — |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M | -$554.1M | -$715.1M | -$361.9M | -$50.7M | -$267.3M |
| EPS, basic | -7.13 | 2.47 | -5.80 | -8.03 | -5.15 | -7.11 | — | — | — | — |
| EPS, diluted | -7.13 | 2.34 | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | -5.46 | -0.86 | -5.49 |
| Shares, diluted (wtd. avg.) | $100.1M | $107.9M | $92.4M | $87.6M | $81.3M | $78.0M | $73.6M | $66.2M | $58.8M | $48.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $801.3M | $1.10B | $428.4M | $966.8M | $2.12B | $1.50B | $835.1M | $370.8M | $599.7M | $122.4M |
| Short-term investments | $138.4M | $251.8M | $1.25B | $1.02B | $0 | $435.9M | $289.7M | $803.1M | $479.4M | $195.4M |
| Receivables | $398.2M | $602.0M | $400.3M | $214.6M | $153.0M | $101.3M | $90.9M | $49.0M | $29.5M | $5.2M |
| Inventory | $914.7M | $750.0M | $322.9M | $204.0M | $186.2M | $232.0M | $171.4M | $125.4M | $83.6M | $12.8M |
| Total current assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373.5M |
| Property, plant and equipment | $345.1M | $340.3M | $227.2M | $180.0M | $191.2M | $190.4M | $129.6M | $97.0M | $43.2M | $37.8M |
| Other intangibles | $28.9M | $26.9M | $29.6M | $7.6M | $14.2M | $13.6M | $12.5M | $11.6M | $14.4M | $8.1M |
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424.1M |
| Accounts payable | $280.8M | $214.4M | $164.9M | $95.9M | $76.7M | $111.1M | $68.1M | $33.8M | $8.5M | $29.7M |
| Short-term debt | — | $0 | $105.5M | $0 | — | — | — | — | — | — |
| Total current liabilities | $1.10B | $731.7M | $653.7M | $619.6M | $452.7M | $416.0M | $264.8M | $173.7M | $88.3M | $75.4M |
| Long-term debt | $140.5M | $1.14B | $1.24B | $1.54B | $563.7M | — | — | $420.6M | $431.1M | $17.7M |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $609.8M | $518.7M | $87.4M |
| Retained earnings | -$4.88B | -$4.21B | -$4.45B | -$3.91B | -$3.21B | -$2.85B | -$2.29B | -$1.58B | -$1.22B | -$1.17B |
| Total equity | $1.14B | $1.53B | $859.3M | $384.9M | $928.0M | $761.8M | $818.2M | $1.03B | $789.2M | $336.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M | $107.5M | -$456.5M | -$388.7M | -$232.0M | -$245.8M |
| Depreciation and amortisation | $44.5M | $37.7M | $44.4M | $41.9M | $38.0M | $26.9M | $24.5M | $12.2M | $8.1M | $5.6M |
| Stock-based compensation | $123.4M | $184.3M | $182.5M | $233.0M | $113.9M | $108.1M | $78.6M | $50.1M | $30.5M | $30.0M |
| Capital expenditure | $102.0M | $137.0M | $76.1M | $30.8M | $38.5M | $82.2M | $59.6M | $61.2M | $12.0M | $5.3M |
| Investing cash flow | $69.6M | $755.6M | -$165.8M | -$1.05B | $495.4M | -$121.7M | $286.7M | -$370.5M | -$178.8M | -$90.2M |
| Financing cash flow | -$168.3M | $124.8M | $125.0M | $232.5M | $561.6M | $682.3M | $642.6M | $530.1M | $888.1M | $378.1M |
| Buybacks | $25.0M | $0 | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177247.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |